Hypoxic repression of pyruvate dehydrogenase activity is necessary for metabolic reprogramming and growth of model tumours

Tereza Golias, Ioanna Papandreou, Ramon Sun, Bhavna Kumar, Nicole V. Brown, Benjamin J Swanson, Reetesh Pai, Diego Jaitin, Quynh Thu Le, Theodoros N. Teknos, Nicholas C. Denko

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Tumour cells fulfil the bioenergetic and biosynthetic needs of proliferation using the available environmental metabolites. Metabolic adaptation to hypoxia causes decreased mitochondrial function and increased lactate production. This work examines the biological importance of the hypoxia-inducible inhibitory phosphorylations on the pyruvate dehydrogenase E1α subunit. Pancreatic cancer cell lines were genetically manipulated to alter the net phosphorylation of PDH E1α through reduced kinase expression or enhanced phosphatase expression. The modified cells were tested for hypoxic changes in phosphorylated E1α, mitochondrial metabolism and growth as xenografted tumours. Even though there are four PDHK genes, PDHK1 is essential for inhibitory PDH phosphorylation of E1α at serine 232, is partially responsible for modification of serines 293 and 300, and these phosphorylations are necessary for model tumour growth. In order to determine the clinical relevance, a cohort of head and neck cancer patient biopsies was examined for phosphorylated E1α and expression of PDHK1. Patients with detectable 232 phosphorylation or expression of PDHK1 tend to have worse clinical outcome. These data show that PDHK1 activity is unique and non-redundant in the family of PHDK enzymes and a PDHK1 specific inhibitor would therefore have anti-cancer activity with reduced chance of side effects from inhibition of other PDHKs.

Original languageEnglish (US)
Article number31146
JournalScientific Reports
Volume6
DOIs
StatePublished - Aug 8 2016
Externally publishedYes

Fingerprint

Pyruvic Acid
Oxidoreductases
Phosphorylation
Growth
Neoplasms
Serine
Pyruvate Dehydrogenase (Lipoamide)
Head and Neck Neoplasms
Pancreatic Neoplasms
Phosphoric Monoester Hydrolases
Energy Metabolism
Lactic Acid
Phosphotransferases
Biopsy
Cell Line
Enzymes
Genes
Hypoxia

ASJC Scopus subject areas

  • General

Cite this

Hypoxic repression of pyruvate dehydrogenase activity is necessary for metabolic reprogramming and growth of model tumours. / Golias, Tereza; Papandreou, Ioanna; Sun, Ramon; Kumar, Bhavna; Brown, Nicole V.; Swanson, Benjamin J; Pai, Reetesh; Jaitin, Diego; Le, Quynh Thu; Teknos, Theodoros N.; Denko, Nicholas C.

In: Scientific Reports, Vol. 6, 31146, 08.08.2016.

Research output: Contribution to journalArticle

Golias, T, Papandreou, I, Sun, R, Kumar, B, Brown, NV, Swanson, BJ, Pai, R, Jaitin, D, Le, QT, Teknos, TN & Denko, NC 2016, 'Hypoxic repression of pyruvate dehydrogenase activity is necessary for metabolic reprogramming and growth of model tumours', Scientific Reports, vol. 6, 31146. https://doi.org/10.1038/srep31146
Golias, Tereza ; Papandreou, Ioanna ; Sun, Ramon ; Kumar, Bhavna ; Brown, Nicole V. ; Swanson, Benjamin J ; Pai, Reetesh ; Jaitin, Diego ; Le, Quynh Thu ; Teknos, Theodoros N. ; Denko, Nicholas C. / Hypoxic repression of pyruvate dehydrogenase activity is necessary for metabolic reprogramming and growth of model tumours. In: Scientific Reports. 2016 ; Vol. 6.
@article{6ff33f48f9034b16892c571caa307fbb,
title = "Hypoxic repression of pyruvate dehydrogenase activity is necessary for metabolic reprogramming and growth of model tumours",
abstract = "Tumour cells fulfil the bioenergetic and biosynthetic needs of proliferation using the available environmental metabolites. Metabolic adaptation to hypoxia causes decreased mitochondrial function and increased lactate production. This work examines the biological importance of the hypoxia-inducible inhibitory phosphorylations on the pyruvate dehydrogenase E1α subunit. Pancreatic cancer cell lines were genetically manipulated to alter the net phosphorylation of PDH E1α through reduced kinase expression or enhanced phosphatase expression. The modified cells were tested for hypoxic changes in phosphorylated E1α, mitochondrial metabolism and growth as xenografted tumours. Even though there are four PDHK genes, PDHK1 is essential for inhibitory PDH phosphorylation of E1α at serine 232, is partially responsible for modification of serines 293 and 300, and these phosphorylations are necessary for model tumour growth. In order to determine the clinical relevance, a cohort of head and neck cancer patient biopsies was examined for phosphorylated E1α and expression of PDHK1. Patients with detectable 232 phosphorylation or expression of PDHK1 tend to have worse clinical outcome. These data show that PDHK1 activity is unique and non-redundant in the family of PHDK enzymes and a PDHK1 specific inhibitor would therefore have anti-cancer activity with reduced chance of side effects from inhibition of other PDHKs.",
author = "Tereza Golias and Ioanna Papandreou and Ramon Sun and Bhavna Kumar and Brown, {Nicole V.} and Swanson, {Benjamin J} and Reetesh Pai and Diego Jaitin and Le, {Quynh Thu} and Teknos, {Theodoros N.} and Denko, {Nicholas C.}",
year = "2016",
month = "8",
day = "8",
doi = "10.1038/srep31146",
language = "English (US)",
volume = "6",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Hypoxic repression of pyruvate dehydrogenase activity is necessary for metabolic reprogramming and growth of model tumours

AU - Golias, Tereza

AU - Papandreou, Ioanna

AU - Sun, Ramon

AU - Kumar, Bhavna

AU - Brown, Nicole V.

AU - Swanson, Benjamin J

AU - Pai, Reetesh

AU - Jaitin, Diego

AU - Le, Quynh Thu

AU - Teknos, Theodoros N.

AU - Denko, Nicholas C.

PY - 2016/8/8

Y1 - 2016/8/8

N2 - Tumour cells fulfil the bioenergetic and biosynthetic needs of proliferation using the available environmental metabolites. Metabolic adaptation to hypoxia causes decreased mitochondrial function and increased lactate production. This work examines the biological importance of the hypoxia-inducible inhibitory phosphorylations on the pyruvate dehydrogenase E1α subunit. Pancreatic cancer cell lines were genetically manipulated to alter the net phosphorylation of PDH E1α through reduced kinase expression or enhanced phosphatase expression. The modified cells were tested for hypoxic changes in phosphorylated E1α, mitochondrial metabolism and growth as xenografted tumours. Even though there are four PDHK genes, PDHK1 is essential for inhibitory PDH phosphorylation of E1α at serine 232, is partially responsible for modification of serines 293 and 300, and these phosphorylations are necessary for model tumour growth. In order to determine the clinical relevance, a cohort of head and neck cancer patient biopsies was examined for phosphorylated E1α and expression of PDHK1. Patients with detectable 232 phosphorylation or expression of PDHK1 tend to have worse clinical outcome. These data show that PDHK1 activity is unique and non-redundant in the family of PHDK enzymes and a PDHK1 specific inhibitor would therefore have anti-cancer activity with reduced chance of side effects from inhibition of other PDHKs.

AB - Tumour cells fulfil the bioenergetic and biosynthetic needs of proliferation using the available environmental metabolites. Metabolic adaptation to hypoxia causes decreased mitochondrial function and increased lactate production. This work examines the biological importance of the hypoxia-inducible inhibitory phosphorylations on the pyruvate dehydrogenase E1α subunit. Pancreatic cancer cell lines were genetically manipulated to alter the net phosphorylation of PDH E1α through reduced kinase expression or enhanced phosphatase expression. The modified cells were tested for hypoxic changes in phosphorylated E1α, mitochondrial metabolism and growth as xenografted tumours. Even though there are four PDHK genes, PDHK1 is essential for inhibitory PDH phosphorylation of E1α at serine 232, is partially responsible for modification of serines 293 and 300, and these phosphorylations are necessary for model tumour growth. In order to determine the clinical relevance, a cohort of head and neck cancer patient biopsies was examined for phosphorylated E1α and expression of PDHK1. Patients with detectable 232 phosphorylation or expression of PDHK1 tend to have worse clinical outcome. These data show that PDHK1 activity is unique and non-redundant in the family of PHDK enzymes and a PDHK1 specific inhibitor would therefore have anti-cancer activity with reduced chance of side effects from inhibition of other PDHKs.

UR - http://www.scopus.com/inward/record.url?scp=84981288024&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84981288024&partnerID=8YFLogxK

U2 - 10.1038/srep31146

DO - 10.1038/srep31146

M3 - Article

VL - 6

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

M1 - 31146

ER -